Pharmacogenomics and the challenge of health disparities

Public Health Genomics

Volumn 12, Issue 3, 2009, Pages 170-179

  Lee, S S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetics; Health disparities; Pharmacogenomics; Population genetics; Race

Indexed keywords

BIOTECHNOLOGY; COST EFFECTIVENESS ANALYSIS; ETHNIC AND RACIAL GROUPS; GENETICS; HEALTH DISPARITY; HUMAN; INVESTMENT; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; ARTICLE; DRUG DESIGN; ETHICS; GENETIC VARIABILITY; HEALTH CARE DISPARITY; PHARMACOGENETICS; RACE; SOCIAL BEHAVIOR;

CONTINENTAL POPULATION GROUPS; DRUG DESIGN; GENETIC VARIATION; HEALTHCARE DISPARITIES; HUMANS; PHARMACOGENETICS; SOCIAL RESPONSIBILITY;

EID: 64549106201     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000189630     Document Type: Review

References (48)

1. Brave New Pharmacy. Time magazine January 15, 2001, http://www.time.com/ time/magazine/article/0,9171,998963,00.html.
2. Ginsburg GS, McCarthy JJ: Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001;19:491-496.
3. Goldstein DB, Tate SK, Sisodya SM: Pharmacogenetics goes genomic. Nat Rev 2003:4:937-947.
4. Lindpaintner K: Pharmacogenetics and the future of medical practice. J Mol Med 2003:81:141-153.
5. Taylor RE: Pharmacological and cultural considerations in alcohol treatment clinical trials: issues in clinical research related to race and ethnicity. Alcohol Clin Exp Res 2003;27:1345-1348.
6. Lee SS: Race, distributive justice and the promise of pharmacogenomics: ethical considerations. Am J Pharmacogenomics 2003;3:385-392.
7. Cooper RS, Kaufman JS, Ward R: Race and genomics. N Engl J Med 2003;348:1166-1170.
8. Sankar P: MEDLINE definitions of race and ethnicity and their application to genetic research. Nat Genet 2003;34:119.
9. Mordini E: Ethical considerations on pharmacogenomics. Pharmacol Res 2004;49:375-379.
10. Kalow W: Pharmacogenetics and personalised medicine. Fundam Clin Pharmacol 2002;16:337-342.
11. Lipton P: Pharmacogenetics: the ethical issues. Pharmacogenomics J 2003;3:14-16.
12. E15 Draft Guidance Terminology on Pharmacogenomics. Center for Biologics Evaluation and Research. Food and Drug Administration 2007 http://www.fda.gov/ Cder/guidance/7619dft.pdf.
13. Conner S: Glaxo chief: our drugs do not work on most patients. The Independent December 8, 2003. http://www.independent.co.uk/news/science/glaxo- chief-our-drugs-do-not-work-on-most-patients-575942.html.
14. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse reactions on hospitalized patients. A meta-analysis of prospective studies. JAMA 1998;279:1200-1205.
15. Ernst FR, Grizzle AJ: Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001;41:192-199.
16. March R, Cheeseman K, Doherty M: Pharmacogenomics - legal, ethical and regulatory considerations. Pharmacogenomics 2001;2:317-327.
17. Veenstra DL, Higashi MK, Phillips KA: Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000;2:E29.
18. Risch N, Burchard E, Ziv E, Tang H: Categorization of humans in biomedical research: genes, race and disease. Genome Biol 2002;3:comment2007.1- comment2007.12.
19. Mehl B, Santell J: Projecting future drug expenditures - 2000. Am J Health Syst Pharm 2000;57:129-138.
20. Tollyma P, Guy P, Altshuler J, Flanagan A, Steiner M: A revolution in R&D. Boston Consulting Group, Boston, 2001.
21. Johnson JA, Bootman JL: Drug-related morbidity and mortality. A cost of illness model. Arch Intern Med 1995;155:1949-1956.
22. Genentech, press release: Genentech Announces Full Year and Fourth Quarter 2005 Results, http://www.gene.com/gene/news/press-releases/display.do? method=detail&-id=9287.
23. Wertz DC: Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J 2003;3:194.
24. Issa AM: Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 2002;1:300-308.
25. Webster A, Martin P, Lewis G, Smart A: Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004;5:663-669.
26. Morley KI, Hall WD: Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. J Mol Med 2004;82:21-30.
27. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM: Impact of genomics on drug discovery and clinical medicine. QJM 2000;93:391-423.
28. Rai AK: Pharmacogenomic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis. Soc Philos Policy 2002;19:246-270.
29. Lee SS, Mountain J, Koenig BA: The meanings of 'race' in the new genomics: implications for health disparities research. Yale J Health Policy Law Ethics 2001;1:33-75.
30. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST;Pharmacogenetics Research Network: Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006;145:749-757.
31. Sillanpaa MJ, Auranen K: Replication in genetic studies of complex traits. Ann Hum Genet 2004;68:646-657.
32. Sankar P, Cho M: Toward a new vocabulary of human genetic variation. Science 2002;298:1337-1338.
33. Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research: Principles and Quantitative Methods. Van Nostrand Reinhold, New York, 1982.
34. Cardon LR, Palmer LJ: Population stratification and spourious allelic association. Lancet 2003;361:598-604.
35. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004;7:895-931.
36. Yasar U, Aklillu E, Canaparo R, Sandberg M, Sayi J, Roh HK, Wennerholm A: Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol 2002;58:555-558.
37. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9 . Pharmacogenetics 2004;8:527-537.
38. Smedley B, Stith A, Nelson A: Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, The National Academic Press, 2002.
39. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M: A comparison of enalapril with hydralazine- isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
40. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057.
41. Kahn J: How a drug becomes 'ethnic': law, commerce, and the production of racial categories in Medicine. Yale J Health Policy Law Ethics 2004;4:1-46.
42. Sankar P, Kahn J: BiDil: race medicine or race marketing? Health Aff (Millwood) 2005;W5:455-463.
43. Lapu-Bula R, Quarshie A, Lyn D, Oduwole A, Pack C, Morgan J, Nkemdiche S, Igho-Pemu P, Onwuanyi A, Li R, Ofili E: The 894T allele of endothelial nitric oxide synthase gene is related to left ventricular mass in African Americans with high-normal blood pressure. J Natl Med Assoc 2005;97:197-205.
44. Bloche MG: Race-based therapeutics. N Engl J Med 2004;351:2035-2037.
45. Food and Drug Administration. 2005. FDA Guidance on the Collection of Race and Ethnicity Data in Clinical Trials, http://www.fda.gov/Cber/gdlns/ racethclin.htm.
46. Epstein S: Inclusion: the Politics of Difference in Medical Research. Chicago, University of Chicago Press, 2007.
47. Satel S: Medicine's Race Problem. Policy Review 110; 2002. http://www.hoover.org/publications/policyreview/3462856.html.
48. McKillop T: Annual Meeting Shareholders Report, 2005.